Cellbion Co

Cellbion Co Tangible Book Value per Share

The Tangible Book Value per Share of Cellbion Co (308430.KQ) as of Oct 31, 2026 is 2,244.70 KRW. In the previous year, Tangible Book Value per Share was 2,850.90 KRW — a change of -21.26% (lower).

Tangible Book Value per Share

2,244.70KRW

YoY

-21.26%

Last updated:

Tangible Book Value per Share of Cellbion Co is 2025 2,244.70 KRW. Tangible Book Value per Share of Cellbion Co was 2024 2,850.90 KRW. It decreases by -21.26% lower compared to the previous year.

The Cellbion Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2021
834.60 KRW
Jan 1, 2022
206.13 KRW
Jan 1, 2023
670.71 KRW
Jan 1, 2024
2,850.90 KRW
Jan 1, 2025
2,244.70 KRW
The Cellbion Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
2,244.70KRW-21.26%
2,850.90KRW+325.06%
670.71KRW+225.38%
206.13KRW-75.30%
834.60KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellbion Co Stock analysis

What does Cellbion Co do? Cellbion Co Ltd generates revenue through the manufacture and sale of pharmaceuticals, including innovative diagnostic and therapeutic new drugs developed by the company. The firm also sells generic prescription drugs and provides contract development and manufacturing organization (CDMO) services for clinical trial drugs. Additionally, the company produces cosmetic products under its own brand. The primary customers are healthcare providers, hospitals, and pharmaceutical companies seeking drug development and manufacturing solutions. The company's product segments include pharmaceuticals, generic prescription drugs, CDMO services, and cosmetics. Key buyers are healthcare institutions, pharmaceutical firms, and consumers purchasing cosmetics. Cellbion Co Ltd targets the Korean market with its domestic operations, focusing on both B2B and B2C segments through its diverse product portfolio. Cellbion Co Ltd's revenue streams are derived from the sale of pharmaceuticals, generic drugs, CDMO services, and cosmetic products. The company's business model emphasizes innovation in drug development alongside traditional pharmaceutical manufacturing, with a focus on serving the domestic Korean healthcare sector and expanding its CDMO capabilities for global clinical trials. Cellbion Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellbion Co stock

Tangible Book Value per Share of Cellbion Co is 2,244.70 KRW in 2025.

Tangible Book Value per Share of Cellbion Co changed from 2,850.90 KRW to 2,244.70 KRW, representing a -21.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Cellbion Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cellbion Co

All Key Metrics — Cellbion Co